![Loader](/assets/loader_gears-10067f3a4c2984639d7edf1d9004a521da8e33a6d776660c0c1ba77f155d23c5.gif)
Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Anidulafungin Action Pathway
Homo sapiens
Drug Action Pathway
Anidulafungin is a semi-synthetic echinocandin antifungal used in the treatment of several types of candida infections. It is known by the brand names Ecalta or Eraxis. It is a treatment for the fungal infections Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.Anidulafungin is commonly used to treat fungal infections in the bloodstream, esophageal candidiasis, fungal peritonitis caused by Candida, intraabdominal abscesses, invasive aspergillosis, and oropharyngeal candidiasis.
As an echinocandin antifungal, Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This prevents the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, which ultimately leads to osmotic instability and cell death.
References
Anidulafungin Pathway References
Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1.
Pubmed: 19724014
Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. doi: 10.2146/ajhp050464.p1.
Pubmed: 16960253
Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. doi: 10.2146/ajhp050464.p2.
Pubmed: 16990627
Ponton J: [The fungal cell wall and the mechanism of action of anidulafungin]. Rev Iberoam Micol. 2008 Jun;25(2):78-82. doi: 10.1016/s1130-1406(08)70024-x.
Pubmed: 18473501
Cappelletty D, Eiselstein-McKitrick K: The echinocandins. Pharmacotherapy. 2007 Mar;27(3):369-88. doi: 10.1592/phco.27.3.369.
Pubmed: 17316149
Vazquez JA: Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005 Jun;27(6):657-73. doi: 10.1016/j.clinthera.2005.06.010.
Pubmed: 16117974
Grover ND: Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396.
Pubmed: 20606829
Vazquez JA: The safety of anidulafungin. Expert Opin Drug Saf. 2006 Nov;5(6):751-8. doi: 10.1517/14740338.5.6.751.
Pubmed: 17044802
Vazquez JA, Sobel JD: Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006 Jul 15;43(2):215-22. doi: 10.1086/505204. Epub 2006 Jun 9.
Pubmed: 16779750
Estes KE, Penzak SR, Calis KA, Walsh TJ: Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy. 2009 Jan;29(1):17-30. doi: 10.1592/phco.29.1.17.
Pubmed: 19113794
Morace G, Borghi E, Iatta R, Montagna MT: Anidulafungin, a new echinocandin: in vitro activity. Drugs. 2009;69 Suppl 1:91-4. doi: 10.2165/11315560-000000000-00000.
Pubmed: 19877740
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings